ASCO 2021 Lung Cancer
Highlights from ASCO 2021: Non-Small Cell Lung Cancer (eBook)
ASCO Lung Cancer Annual Meetingv2.indd Featuring… 5-year PACIFIC data hold strong in NSCLC...
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab with Stereotactic Body Radiotherapy
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Durvalumab after chemoradiation proven safe in elderly NSCLC patients
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Doubling overall survival in US veterans with stage 3 non-small cell lung cancer
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
5-year PACIFIC data hold strong in NSCLC
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Doubling overall survival in US veterans with stage 3 non-small cell lung cancer
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Novel Imaging Biomarkers Identify Stage III NSCLC Therapy Response
A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients...
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
A 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Pembro-Chemo Combo Holds Promise for Stage III NSCLC
Good anti-tumor activity and manageable safety profile seen When added to concurrent...
Amivantamab/Lazertinib Combo Shows Benefit in Relapsed NSCLC
Confirmed response seen in patients who relapse after osimertinib Patients with non-small cell...
